Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
The buyout, announced last summer, drew the attention of federal regulators at the Federal Trade Commission, concerned that competition for ambulatory surgery services would be stifled by the merger. To appease the agency, Ascension has agreed to divest from some centers previously owned by Amsurg.
When Mayo Clinic and Microsoft announced last week that they’re partnering to develop a frontier AI model for healthcare, observers could see where Mayo’s expertise in advanced digital medicine would interest Microsoft. The Big Tech behemoth has not been coy about its healthcare ambitions.
Senate Bill 196 was signed into law by Gov. Ned Lamont a year after the state saw Prospect Medical Holdings, an investor-backed health system, fall into bankruptcy as investors extracted hundreds of millions of dollars in fees from its hospitals.
The lawsuit against Find a Black Doctor was filed by Travis Morrell, MD—a dermatologist based in Colorado—who alleges he was harmed by being excluded from the directory on the basis of race. His case has the backing of the conservative-aligned advocacy group Do No Harm.
Teladoc, the popular telehealth platform, will provide urgent care, dermatology and nutrition support through Walmart’s existing virtual patient care platform. The companies made the announcement Thursday.
U.S. House Rep. Greg Murphy, MD (R-NC), scolded the CEO of NYU Langone for buying the expensive ad, requesting in an open letter that the hospital release financial data related to its cost.
New data from the Private Equity Stakeholder Project reveals that, while 11% of all-sector bankruptcies were filed by organizations with a history of ownership by investment firms, that number rises to 21% for healthcare.
If 25% tariffs go into effect, it could have a big impact on the cost of medical imaging and radiotherapy systems, with many manufacturing facilities in Mexico.
Standing FDA guidance reflects concern over physicians deferring to AI-aided CDS recommendations when pressed for time or uncertain of their own judgments. Is that stance outdated?